Momentum Stock Watch: Ironwood Pharmaceuticals, Inc. (IRWD)

Company Profile:

Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Recent News:

On Jan.04, 2017, the company announced the appointment of Amy Schulman to its board of directors. She currently holds key leadership roles at two biotech companies, serving as chief executive officer and co-founder of Lyndra, Inc., and executive chair of SQZ Biotech.

On Jan.04, 2017, the company announced the U.S. Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for DUZALLO™ (fixed-dose combination of lesinurad and allopurinol) for the treatment of hyperuricemia in patients with uncontrolled gout.

On Dec.22, 2016, Ironwood Pharmaceuticals, Inc. (IRWD) and Allergan plc (AGN) announced topline data from a Phase IIb clinical trial evaluating an investigational linaclotide colonic release-2 (CR2) formulation in adult patients with irritable bowel syndrome with constipation (IBS-C).


Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



IRWD’s strengths can be seen in its strong growth compared with its peers. Technical indicators signal the bullish signs, as there is a bullish cross in MACD and Stochastic Oscillator. RSI stands at 55.69 with positive bias. We rate Ironwood Pharmaceuticals, Inc. (IRWD) a STRONG BUY.

About the Author

has written 14644 stories on this site.

Copyright © 2012 Nine Stocks